

April 5, 2019

By Electronic Mail

Vermont Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

NEW PRESCRIPTION DRUG NOTIFICATION

In compliance with 18 V.S.A. § 4637, EMD Serono hereby provides written notice that on April 2, 2019 it introduced the following prescription drug to market:

- Mavenclad® (cladribine) 10 mg per tablet

Kind Regards,



Daniel C. Barks
Director, NA Pricing Governance and MA&CS Operational Effectiveness
(781) 681 - 2310
daniel.barks@emdserono.com



EMD Serono

One Technology Place
Rockland MA 02370

emdserono.com

1 of 1

EMD Serono is a business of Merck KGaA,
Darmstadt, Germany.